The North America Narcolepsy Therapeutics Market would witness market growth of 9.8% CAGR during the forecast period (2022-2028).
There are two different forms of narcolepsy recognized by the International Classification of Sleep Disorders-Third Edition diagnostic criteria: type 1 and type 2. Chronic daily extreme sleepiness lasting less than three months, mean sleep latency of fewer than eight minutes, and two or more sleep-onset rapid eye movements on the Multiple Sleep Latency Test are all criteria that all types share. The cataplexy and/or low levels of hypocretin 1 in the cerebrospinal fluid (CSF) are additional diagnostic criteria for NT1 (orexin A).
The NT2 criteria include the absence of cataplexy, normal or unmeasured levels of hypocretin 1 in the CSF and the absence of any other condition (including medication side effects or discontinuation) that could explain the results of the EDS and/or MSLT. Many people who have narcolepsy also have unsteady, interrupted sleep, which can include frequent nighttime awakenings. The daily activities of narcoleptics can be affected. People who have narcolepsy may unintentionally nod off while engaging in activities like talking, eating, or driving.
The treatment for sleep disorders is in greater demand in both the United States and Canada. The market is expected to be driven by the rising prevalence of narcoleptic disorders, higher awareness, and high healthcare spending. The other elements projected to support revenue growth include favorable reimbursement regulations for treatments, a solid clinical pipeline, and rising stress levels. The high frequency of narcolepsy in industrialized nations like the United States would encourage more people to use narcolepsy treatments, fueling the expansion of this market.
The US market dominated the North America Narcolepsy Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,071.6 million by 2028.The Canada market is poised to grow at a CAGR of 12.3% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.3% during (2022 - 2028).
Based on Type, the market is segmented into Narcolepsy with Cataplexy, Narcolepsy without Cataplexy and Secondary Narcolepsy. Based on Product, the market is segmented into Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Narcolepsy Therapeutics Market is Estimated to reach $5 Billion by 2028, at a CAGR of 10.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Jazz Pharmaceuticals plc, Shionogi & Co., Ltd., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc. (Arena Pharmaceuticals, Inc.), Bioprojet, Takeda Pharmaceutical Company Limited, Ligand Pharmaceuticals, Inc., and Graymark Healthcare, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Narcolepsy with Cataplexy
- Narcolepsy Without Cataplexy
- Secondary Narcolepsy
By Product
- Sodium Oxybate
- Selective Serotonin Reuptake Inhibitor
- Central Nervous System Stimulants
- Tricyclic Antidepressants
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Jazz Pharmaceuticals plc
- Shionogi & Co., Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
- Bioprojet
- Takeda Pharmaceutical Company Limited
- Ligand Pharmaceuticals, Inc.
- Graymark Healthcare, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Narcolepsy Therapeutics Market, by Type
1.4.2 North America Narcolepsy Therapeutics Market, by Product
1.4.3 North America Narcolepsy Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Narcolepsy Therapeutics Market by Type
3.1 North America Narcolepsy with Cataplexy Market by Country
3.2 North America Narcolepsy Without Cataplexy Market by Country
3.3 North America Secondary Narcolepsy Market by Country
Chapter 4. North America Narcolepsy Therapeutics Market by Product
4.1 North America Sodium Oxybate Market by Country
4.2 North America Selective Serotonin Reuptake Inhibitor Market by Country
4.3 North America Central Nervous System Stimulants Market by Country
4.4 North America Tricyclic Antidepressants Market by Country
4.5 North America Others Market by Country
Chapter 5. North America Narcolepsy Therapeutics Market by Country
5.1 US Narcolepsy Therapeutics Market
5.1.1 US Narcolepsy Therapeutics Market by Type
5.1.2 US Narcolepsy Therapeutics Market by Product
5.2 Canada Narcolepsy Therapeutics Market
5.2.1 Canada Narcolepsy Therapeutics Market by Type
5.2.2 Canada Narcolepsy Therapeutics Market by Product
5.3 Mexico Narcolepsy Therapeutics Market
5.3.1 Mexico Narcolepsy Therapeutics Market by Type
5.3.2 Mexico Narcolepsy Therapeutics Market by Product
5.4 Rest of North America Narcolepsy Therapeutics Market
5.4.1 Rest of North America Narcolepsy Therapeutics Market by Type
5.4.2 Rest of North America Narcolepsy Therapeutics Market by Product
Chapter 6. Company Profiles
6.1 Jazz Pharmaceuticals plc
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Approvals and Trials:
6.2 Shionogi & Co., Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expenses
6.3 Teva Pharmaceutical Industries Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional & Segmental Analysis
6.4.4 Research & Development Expense
6.5 Bioprojet
6.5.1 Company Overview
6.5.2 Recent strategies and developments:
6.5.2.1 Partnerships, Collaborations, and Agreements:
6.6 Takeda Pharmaceutical Company Limited
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.7 Ligand Pharmaceuticals, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Graymark Healthcare, Inc.
6.8.1 Company Overview
TABLE 1 North America Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 2 North America Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 3 North America Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 4 North America Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 5 North America Narcolepsy with Cataplexy Market by Country, 2018 - 2021, USD Million
TABLE 6 North America Narcolepsy with Cataplexy Market by Country, 2022 - 2028, USD Million
TABLE 7 North America Narcolepsy Without Cataplexy Market by Country, 2018 - 2021, USD Million
TABLE 8 North America Narcolepsy Without Cataplexy Market by Country, 2022 - 2028, USD Million
TABLE 9 North America Secondary Narcolepsy Market by Country, 2018 - 2021, USD Million
TABLE 10 North America Secondary Narcolepsy Market by Country, 2022 - 2028, USD Million
TABLE 11 North America Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 12 North America Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 13 North America Sodium Oxybate Market by Country, 2018 - 2021, USD Million
TABLE 14 North America Sodium Oxybate Market by Country, 2022 - 2028, USD Million
TABLE 15 North America Selective Serotonin Reuptake Inhibitor Market by Country, 2018 - 2021, USD Million
TABLE 16 North America Selective Serotonin Reuptake Inhibitor Market by Country, 2022 - 2028, USD Million
TABLE 17 North America Central Nervous System Stimulants Market by Country, 2018 - 2021, USD Million
TABLE 18 North America Central Nervous System Stimulants Market by Country, 2022 - 2028, USD Million
TABLE 19 North America Tricyclic Antidepressants Market by Country, 2018 - 2021, USD Million
TABLE 20 North America Tricyclic Antidepressants Market by Country, 2022 - 2028, USD Million
TABLE 21 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 22 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 23 North America Narcolepsy Therapeutics Market by Country, 2018 - 2021, USD Million
TABLE 24 North America Narcolepsy Therapeutics Market by Country, 2022 - 2028, USD Million
TABLE 25 US Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 26 US Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 27 US Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 28 US Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 29 US Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 30 US Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 31 Canada Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 32 Canada Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 33 Canada Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 34 Canada Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 35 Canada Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 36 Canada Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 37 Mexico Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 38 Mexico Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 39 Mexico Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 40 Mexico Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 41 Mexico Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 42 Mexico Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 43 Rest of North America Narcolepsy Therapeutics Market, 2018 - 2021, USD Million
TABLE 44 Rest of North America Narcolepsy Therapeutics Market, 2022 - 2028, USD Million
TABLE 45 Rest of North America Narcolepsy Therapeutics Market by Type, 2018 - 2021, USD Million
TABLE 46 Rest of North America Narcolepsy Therapeutics Market by Type, 2022 - 2028, USD Million
TABLE 47 Rest of North America Narcolepsy Therapeutics Market by Product, 2018 - 2021, USD Million
TABLE 48 Rest of North America Narcolepsy Therapeutics Market by Product, 2022 - 2028, USD Million
TABLE 49 Key Information – Jazz Pharmaceuticals plc
TABLE 50 Key Information – Shionogi & Co., Ltd.
TABLE 51 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 52 Key Information – Pfizer, Inc.
TABLE 53 Key Information – Bioprojet
TABLE 54 Key Information – Takeda Pharmaceutical Company Limited
TABLE 55 Key Information – Ligand Pharmaceuticals, Inc.
TABLE 56 Key Information – Graymark Healthcare, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: Jazz Pharmaceuticals PLC